Why did AELIS.PA stock spike today?

AELIS.PA stock spiked on heavy buying and large block trades after open. Volume hit **106,388**, far above the **27,605** average. Market scanners also flagged peer comparisons and earnings-transcript interest on news platforms.

What are the main risks for AELIS.PA stock holders?

Main risks are clinical trial outcomes, continued losses with **EPS -0.60**, and thin typical liquidity. Analyst sentiment is mixed, and a failed readout would likely cause sharp declines.

What price targets or forecasts exist for AELIS.PA stock?

Meyka AI's forecast model projects **€1.66** monthly and **€7.17** quarterly. The monthly projection implies **6.41%** upside. Forecasts are model-based projections and not guarantees.

How should traders size positions in AELIS.PA stock after a volume spike?

Given the stock's small market cap and binary biotech risk, use smaller position sizes and defined stops. High intraday volume helps execution but does not reduce clinical event risk.

EU Stocks

AELIS.PA Aelis Farma EURONEXT up 28.40% intraday 27 Jan 2026: Volume spike note

ByDanny Kontos January 27, 2026January 27, 2026

AELIS.PA stock jumped 28.40% intraday to €1.56 on 27 Jan 2026 on EURONEXT. The move paired a price gap from the previous close of €1.22 with heavy volume at 106,388 shares, almost four times the average. Traders are watching Aelis Farma SA given its biotech pipeline and a clear short-term re-rating. We review intraday drivers, technicals, valuation, and quick forecasts to help traders parse today’s high-volume signal.